Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioTherapeutics
Oxford BioTherapeutics
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Boehringer Ingelheim receives US FDA Fast Track designation for BI 764532
BI 764532 is a potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung
Research & Development
Oxford BioTherapeutics relocates UK headquarters to the Oxford Science Park
The new facilities comprise state-of-the-art office and custom laboratory spaces that will support and enhance OBT’s growing target discovery and drug development capabilities
Manufacturing
Oxford BioTherapeutics and Boehringer Ingelheim extend cancer immunology partnership
The two companies have extended their existing collaboration by a further two years, aiming to develop novel cancer immunotherapies
Research & Development
Boehringer Ingelheim and OBT advance oncology candidate
The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by Oxford BioTherapeutics’ proprietary OGAP target discovery platform
Recruitment
Oxford BioTherapeutics appoints Chief Medical Officer
Research & Development
Oxford BioTherapeutics licenses Nerviano's drug-linker technology
To develop novel antibody drug conjugates
Research & Development
Oxford BioTherapeutics hires Head of Clinical Development
Dr Eugen Leo takes the position
Subscribe now